Cannabis Law Report

AUGUST 2, 2021

Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. 2, 2021 /PRNewswire/ — SciSparc Ltd. Key findings from the pre-clinical trial are as follows: SCI-160 significantly alleviates pain up to 6 hours after injection as compared with vehicle-treated animals.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD’s superior potency over CBD by factor of 8,000 times.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

OCTOBER 19, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m. ET in Track 1. MyMD Chief Scientific Officer Adam Kaplin, M.D.,

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

The Cannigma

JANUARY 13, 2023

The authors noted that while “promising data are emerging on the possible role of ECS in migraine…proper placebo-controlled trials are needed to establish a therapeutic role for cannabinoids.” 1 A 2008 study found serotonin and endocannabinoid levels, including anandamide, were lower in people with chronic migraines.

Terpenes 132

Terpenes Strains THC Treatment 132

Canna Care Docs

DECEMBER 16, 2020

The New Year is fast approaching, and if you’re not feeling entirely hopeful about 2021, you’re certainly not alone. Among the 100-plus chemicals called cannabinoids in the cannabis plant, the two that are best known for their medicinal benefits are tetrahydrocannabinol (THC) and cannabidiol (CBD). Chronic pain.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

Healer

DECEMBER 17, 2021

November 5, 2021. Cannabidiol (CBD) is a well-known component of hemp with diverse health benefits such as reducing pain and inflammation after physical activity, relief from occasional sleeplessness, as well as improvements in focus, mood and resilience to stress. Hospital Pharmacy (2021): 0018578720985438. References.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

JANUARY 24, 2022

The marijuana segment dominated the market in 2021. The CBD segment dominated the market in 2021 due to the growing awareness about the positive effects of CBD for the treatment of various medical conditions, such as chronic pain, cancer & multiple sclerosis. In 2021, the recreational segment dominated the market.

Legalization 52

Legalization Supply Chain Chronic Pain Recreational 52

Healer

DECEMBER 17, 2021

November 5, 2021. Cannabidiol (CBD) is a well-known component of hemp with diverse health benefits such as reducing pain and inflammation after physical activity, relief from occasional sleeplessness, as well as improvements in focus, mood and resilience to stress. Hospital Pharmacy (2021): 0018578720985438. [5] References. [1]

CBD 52

CBD THC Conditions Medicine 52

Veriheal

AUGUST 31, 2020

However, social and economic barriers like racial stereotypes and lack of access to care centers have historically barred Hispanic community members from seeking medical cannabis and participating in clinical trials. The post Veriheal’s Innovation in Cannabis Scholarship 2020 Winners appeared first on Cannabis Central.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

NOVEMBER 24, 2021

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Australian health authorities advise that cannabis should not be used as a first line of treatment (Kotsirilos and McGregor 2021 ). Conclusions.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

DECEMBER 30, 2019

State lawmakers passed Assembly Bill 420 , which authorizes the University of California’s Center for Medicinal Cannabis Research to cultivate cannabis for clinical trials. Specifically, it expands the pool of patients eligible for cannabis therapy to include those with chronic pain, menstrual cramps, and epilepsy.

Legislation 59

Legislation Patients Access Banking 59